In a previous study that matched populations from the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN 6) and Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) cardiovascular outcome trials using the propensity score method, semaglutide reduced 3-point MACE (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) by 26% compared to dulaglutide, although the reduction was not statistically significant (hazard ratio [HR], 0.74
Go deeper: As WBUR's Priyanka Dayal McCluskey recently reported, the $200 million that BCBS spent on GLP drugs in 2024 was a main driver of why health care premiums for all customers soared this year
04 How do I know which NAD vial size is right for me
Gao Z, Li Q, Wu X, Zhao X, Zhao L, Tong X
Access, Cost, and Patient Adherence in Real-World Settings While clinical trial data is compelling, real-world implementation presents unique obstacles